The treatment paradigm for CLL is evolving as new agents enter the landscape. While this is good news, it comes with its own set of challenges such as how to identify optimal sequence strategies and measure depth and durability of response. To understand where we’re at right now, we spoke to Professor Jan Burger from the MD Anderson Cancer Centre at the University of Texas and Professor Stephen Opat, Director of Clinical Oncology at Monash Health.

This podcast was sponsored by Janssen. The content is based on published studies and the opinions of independent experts. The views expressed are not necessarily those of Janssen.

PLEASE REVIEW PRODUCT INFORMATION BEFORE PRESCRIBING (available from www.janssen.com.au/imbruvica_PI).